PTJ
BPMC

Paul Tudor Jones’s Blueprint Medicines BPMC Stock Holding History

Paul Tudor Jones’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-468,623
Closed -$60.1M – 3381
2025
Q2 		$60.1M Buy
468,623
+446,612
+2,029% +$46.4M 0.13% 101
2025
Q1 		$1.95M Buy
22,011
+13,911
+172% +$1.36M 0.01% 1364
2024
Q4 		$706K Buy
+8,100
New +$742K ﹤0.01% 1985
2023
Q2 		– Sell
-9,663
Closed -$435K – 2458
2023
Q1 		$435K Buy
+9,663
New +$435K 0.01% 1702
2022
Q4 		– Sell
-28,444
Closed -$1.87M – 2403
2022
Q3 		$1.87M Buy
28,444
+9,639
+51% +$619K 0.04% 568
2022
Q2 		$950K Buy
18,805
+8,700
+86% +$510K 0.02% 920
2022
Q1 		$646K Buy
10,105
+2,253
+29% +$162K 0.02% 1133
2021
Q4 		$841K Sell
7,852
-3,108
-28% -$325K 0.01% 1115
2021
Q3 		$1.13M Sell
10,960
-70,299
-87% -$6.55M 0.02% 1075
2021
Q2 		$7.15M Buy
+81,259
New +$7.45M 0.14% 127
2018
Q1 		– Sell
-10,582
Closed -$798K – 1012
2017
Q4 		$798K Buy
10,582
+6,716
+174% +$473K 0.02% 426
2017
Q3 		$269K Sell
3,866
-1,751
-31% -$93.6K 0.01% 865
2017
Q2 		$285K Sell
5,617
-40,344
-88% -$1.71M 0.01% 775
2017
Q1 		$1.84M Buy
45,961
+3,402
+8% +$122K 0.06% 209
2016
Q4 		$1.19M Buy
42,559
+33,156
+353% +$999K 0.03% 300
2016
Q3 		$279K Buy
+9,403
New +$234K 0.01% 1066

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Paul Tudor Jones's BPMC Position: Q3 2025 in Review

Paul Tudor Jones sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 468,623 shares — an estimated $60.1M sold.

Paul Tudor Jones first reported a position in BPMC in Q3 2016 and held it in 16 quarters. The position peaked at $60.1M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Paul Tudor Jones reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 468,623 Blueprint Medicines shares in Q3 2025, an estimated $60.1M.
  • Paul Tudor Jones first reported a position in Blueprint Medicines in Q3 2016 and held it in 16 quarters.
  • Paul Tudor Jones's Blueprint Medicines position peaked at $60.1M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.